Pathogen | Africa | Americas | Eastern Mediterranean | Europe | South East Asia | Western Pacific | WHO key points |
---|---|---|---|---|---|---|---|
Staphylococcus aureus (beta-lactam resistant; i.e., MRSA) | 12–80 | 21–90 | 10–53 | 0.3–60 | 10–26 | 4–84 | Data on MRSA proportions among S. aureus were obtained from 44 % of member states; most reported MRSA proportions exceed 20 % in all WHO regions and even exceed 80 % in some reports. |
Streptococcus pneumoniae (penicillin-resistant) | 3–16 | 0–48 | 13–34 | 0–61 | 47–48 | 17–64 | Data were obtained from only 35 % of member states; non-susceptibility to penicillin has been detected in all WHO regions. |
Escherichia coli (resistant to third-generation cephalosporins) | 2–70 | 0–48 | 22–63 | 3–82 | 16–68 | 0–77 | Data on E. coli resistance to third-generation cephalosporins were obtained from 44 % of member states; reports consistently disclosed high resistance rates to the last-generation drugs commonly used to treat serious infections. |
Klebsiella pneumoniae (resistant to third-generation cephalosporins) | 8–77 | 4–71 | 22–50 | 2–82 | 34–81 | 1–72 | The majority of sources reported more than 30 % resistance in K. pneumoniae to third-generation cephalosporins in the sampled populations; resistance proportions exceeding 50 % were reported from all WHO regions. |
Klebsiella pneumoniae (resistant to carbapenems) | 0–4 | 0–11 | 0–54 | 0–68 | 0–8 | 0–8 | Rates of carbapenem resistance exceeding 50 % have been reported in some patient groups, for which few, if any, alternative treatment options are available. |